secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001193125-24-168554
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech gets FDA IND clearance & Fast Track for hepatitis delta combo therapy
--------------------------------------------------------------------------------

- FDA cleared IND and granted Fast Track for tobevibart + elebsiran for chronic hepatitis delta.
- Phase 2 SOLSTICE 24-week data expected Q4 2024; preliminary data showed high virologic response.
- Company plans ECLIPSE trial to support potential registration, comparing combo to standard of care.
- CEO Marianne De Backer says IND clearance underscores potential to transform treatment landscape.
- Hepatitis delta affects at least 12 million people globally; considered most severe viral hepatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312524168554/0001193125-24-168554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312524168554/d835539d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-168554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer